05/16/2025
Excited to announce a new FDLI webinar happening on May 29!
On April 1, FDA eliminated approximately 3,500 positions. What do these reductions and organizational changes mean for how industry engages with FDA on product reviews, postmarket compliance, guidances, and public health research? Panelists will offer insights into FDA’s evolving structure, implications of staff departures on product review and approval, potential disruptions to user fee negotiations, and practical tips for regulated industry on how to move forward during this period of transition.
Speakers:
E. Cartier Esham, CEO and Founder, Esham Strategies, LLC
Danielle C. Humphrey, VP Compliance Officer & Chief Regulatory Counsel, Becton Dickinson (BD)
Kurt R. Karst, Director, Hyman, Phelps & McNamara, P.C.
Moderated By Rachel Turow, Of Counsel, Skadden, Arps, Slate, Meagher & Flom LLP
Register now at http://bit.ly/44AFfmw